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INTRODUCTION
Overexpression of bcl-2 protein is thought to allow cells that are genetically unstable to avoid apoptosis and become tumorigenic. In addition to its importance in cancer development, high bcl-2 expression in hematological tumors is frequently an obstacle to cancer chemotherapy, since bcl-2 overexpression has been shown to confer cellular resistance to a variety of anticancer drugs. 1, 2 The clinical relevance of bcl-2 overexpression is clearly evident in the development of B cell chronic lymphocytic leukemia (CLL). CLL is the most prevalent form of adult leukemia in the Western world and is considered an incurable disease. CLL is indolent during most of its clinical course and the clonal B cells accumulate during the indolent phase by avoiding apoptosis. 3 High-level expression of bcl-2 mRNA and protein is often seen in CLL despite the absence of evidence for gene rearrangements that are known to enhance bcl-2 transcription. [4] [5] [6] This raised the question whether overexpression of bcl-2 protein in CLL is a consequence of increased bcl-2 mRNA stability.
The majority of the elements that regulate mRNA stability map to the 3'-untranslated region (3'-UTR) of mRNAs. The 3' UTR has been described as "a molecular hotspot for pathology", 7 and modifications of specific elements within the 3' UTR can profoundly affect the expression and metabolic fate of the mRNA. 8 Prominent among these elements are the AU-rich elements (AREs). AREs generally contain multiple copies of the AUUUA pentamer and have a high content of U or A-U. AUUUA motifs are often associated with destabilization of shortlived cytokine and protooncogene mRNAs. 9, 10 The 3'-UTR of bcl-2 mRNA contains four potential AREs. ARE-1 has the highest concentration of AUUUA pentamers of the four AREs and has potent bcl-2 mRNA destabilizing activity. 11, 12 Examination of different mRNAs suggests only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From that the destabilizing effects of an ARE and AUUUA motifs can be increased or decreased by interactions with ARE-binding proteins. 13, 14 The manner in which ARE-binding proteins modulate mRNA decay is not completely clear. With some mRNAs, binding of specific proteins to the ARE stabilizes the mRNA in a circular form and impedes deadenylation of the poly(A) tail by poly(A) ribonuclease (PARN). 15, 16 In contrast, following shortening of the poly(A) tail, the binding of destabilizing proteins to the ARE can result in recruitment of an exosome to the AREmRNAs, leading to rapid degradation of the mRNA. 17, 18 Nucleolin is a multifunctional protein that is a member of the RNP-containing family of RNA binding proteins. This protein binds to the 3'-UTR of amyloid precursor protein (APP) mRNA and enhances APP mRNA stability. 19, 20 Nucleolin is also required for the stabilization of IL-2 mRNA that occurs during T cell activation. 21 Recent studies have identified nucleolin as a bcl-2 mRNA stabilizing protein in HL-60 leukemia cells. 22, 23 It binds specifically to the ARE-1 instability element in the 3'-UTR of bcl-2 mRNA and protects bcl-2 mRNA from ribonuclease degradation. However, it is not known whether the increased levels of bcl-2 mRNA and protein in CLL cells are related to stabilization of bcl-2 mRNA by nucleolin. To address this question, the studies described herein examined the stability of bcl-2 mRNA in CLL cells isolated from patients compared to normal B cells from healthy volunteers. This novel, post-transcriptional mechanism of bcl-2 overexpression in CLL proposed here may provide an answer to the longstanding question regarding the mechanism by which bcl-2 mRNA and protein are overexpressed in CLL in the absence of enhanced bcl-2 transcription. Stabilization of bcl-2 mRNA by nucleolin would also be consistent with the indolent nature of this disease in which CLL cells accumulate by avoiding apoptosis. Immuno-Blot Analysis. Immunoblotting was done as previously described. 23 For determination of cytosolic nucleolin and total cellular bcl-2 proteins, freshly isolated CD19 + B cells were lysed for 15 min on ice in lysis buffer, 23 followed by centrifugation at 10,000 x g for 15 min at 4°C to yield S10 extracts. Protein concentrations were determined by the BCA assay (Pierce, Lockford, IL The PCR products were resolved on a 2% agarose gel, stained with ethidium bromide, and visualized with a Typhoon PhosphorImager. Product formation was quantitated by determining the integrated density value of each band using ImageQuant TL software (GE Healthcare) and normalized to the amount of β-actin gene product. patients or two normal human volunteers. Cytoplasmic S100 extracts were prepared from the freshly isolated cells by incubating the cells in lysis buffer for 20 min on ice, followed by successive centrifugation of the supernatants at 10,000 x g for 2 min at 4°C, and then at 100,000
Binding of Bcl-2 ARE-1 to Nucleolin in Extracts of
x g for 1 h at 4°C. Aliquots of the S100 fractions containing 100 µ g of protein were precleared with protein G agarose beads (Santa Cruz Biotechnology) and mouse IgG (1 µ g) in lysis buffer containing 150 mM KCl. The S100 fractions were then incubated with 0.25 nM (25 fmol) only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From polyadenylated CR-ARE RNAs were used per decay reaction, which was performed as described by Ford and Wilusz (1999) . 24 Typically, a 70 µl reaction mixture contained 16 µl of 10% polyvinyl alcohol, 5 µl of a 12.5 mM ATP/250 mM phosphocreatine mixture, 5 µl of 500 ng/µl poly(A) (GE Healthcare), 5 µl 32 P-labeled transcript (~175 nM) and 8-10 µg of protein from either CLL or normal B cell S100 extracts. In some of the reactions purified recombinant nucleolin was added. Recombinant nucleolin was generated using a bacterial expression vector (pET21a) containing c-DNA sequences that code for residues 284-707 of human nucleolin [∆1-283 Nuc-(His) 6 ]. 25 The histidine-tagged nucleolin fragment was expressed in E. coli and purified on a Ni ++ -NTA column as previously described. 22 Samples were incubated at 30°C and the reaction was stopped at various times by transferring 15 µl aliquots to 100 µl of stop buffer (400 mM NaCl, 25 mM Tris-HCl (pH 7.5), 0.1% SDS) and immediately extracting with 100 µl of only.
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After electrophoresis, gels were fixed, dried and analyzed by phosphorimaging. siRNA plasmids using Lipofectamine2000 (Invitrogen), and after 48 hr the cells were selected in medium containing 500 µg/ml of G418. The medium was replaced daily with fresh G418 medium. After 8 days, resistant clones were picked and the cells were propagated for 20 days prior to analysis of nucleolin and bcl-2 protein levels. The nucleolin and scrambled siRNA sequences in the G418-resistant clones were confirmed by sequencing.
Generation of Nucleolin
Total RNA was extracted from the transfectants using Trizol reagent (Invitrogen) according to the manufacturer's protocol. Expression of nucleolin and bcl-2 mRNA levels were analyzed by quantitative polymerase chain reaction (qPCR) in the stable clones. cDNA synthesis was performed using 1 µg total RNA as described above. The primers for nucleolin and bcl-2 were 5' CCA GCCATCCAAAACTCTGT 3' and 5' TAACTATCCTTGCCCGAACG 3' and 5' ATGTGTGTGGAGAGCGTCAA 3' and 5' ACAGTTCCACAAAGGCATCC 3', respectively.
The primers for β -actin were 5' AAATCTGGCACCACACCTTC3' and 5' 
RESULTS

Patient
Characteristics. Seventeen patients with CLL were studied. Although selected only on the basis of willingness to donate blood cells, the subjects were predominantly early stage and untreated (Table 1) . Median age, sex, and absolute lymphocyte counts were typical of CLL patients in general. Interphase cytogenetic analysis by fluorescent in situ hybridization, using a limited panel of probes, was available for 8 subjects. Two had no abnormalities, and five had chromosome 13 deletions involving band q14, either alone (3 patients) or with mutation of ATM (1 patient) or duplicated chromosome 12 (1 patient). A single patient had an isolated p53 mutation.
Overexpression of Nucleolin and Bcl-2 Proteins in CLL Cells Compared to Normal B Cells.
Nucleolin has recently been identified as a bcl-2 mRNA stabilizing protein in HL-60 leukemia cells. 22, 23 Thus, the initial studies compared the relative levels of nucleolin and bcl-2 proteins in purified CD19 + CLL cells and normal CD19 + B cells by immuno-blotting S10 extracts of these cells. We chose to analyze S10 extracts in order to permit measurement of non nuclear nucleolin and mitochondrial bcl-2 protein in the same cell extract. In particular, nucleolin in the cytoplasm would be directly involved in bcl-2 mRNA stabilization.
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To accurately compare the immuno-blot results from different patients, the integrated density values (IDV) of the nucleolin and the bcl-2 protein bands in the immuno-blots were normalized to the IDV values obtained from known amounts of nucleolin and bcl-2 protein external standards. This analysis revealed that bcl-2 and nucleolin proteins were 11-fold elevated (p<0.001) and 26-fold elevated (p<0.001), respectively, in CLL cells from 17 patients compared to B cells from 9 normal volunteers (Fig 1) . In addition, the enhanced bcl-2 protein levels were positively correlated with the increased nucleolin levels (Pearson's correlation = 0.83, p<0.001).
Total cellular nucleolin levels were higher in CLL cells than normal B cells, primarily as a result of the much higher levels of cytoplasmic nucleolin in the CLL cells. No statistically significant differences in the nuclear levels of nucleolin were observed between CLL and normal B cells (p>0.05). The nuclear protein histone 2B was not detected in western blots of the S10 extracts from either CLL or normal B cells (data not shown). Thus, the presence of high levels of nucleolin in the S10 cytoplasmic extracts of CLL cells was not consistent with contamination of the S10 extracts with nuclear nucleolin.
Results from confocal microscopy studies (Fig 2) were consistent with the immunoblotting data. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From reports that nucleolin is present in the plasma membranes of certain cells, 26, 27 although further studies will be required to verify the localization of nucleolin in the plasma membrane of CLL cells. This method has been used successfully to determine the relative rate of mRNA transcription and mRNA decay in a variety of cells. 28, 29 Equal amounts of total RNA from each sample were reverse-transcribed and real-time PCR was performed with two sets of primers. One reaction contained primers that anneal to the first intron (to selectively amplify hnRNA) and one with primers that anneal to sequences in two adjacent exons (to selectively amplify spliced, mature RNA). We found that the ratio of bcl-2 mRNA to bcl-2 hnRNA was about 3-fold higher for CLL cells compared to normal B cells (p<0.001) (Fig 3) . The 3-fold higher ratio bcl-2 mRNA / bcl-2 hnRNA for CLL cells was entirely the result of an increase in the bcl-2 mRNA level in CLL cells To further investigate whether bcl-2 mRNA is stabilized in CLL cells, the stability of bcl-2 RNA transcripts was examined in extracts prepared from purified CLL cells and normal B cells using an in vitro RNA decay system. 24 Capped and polyadenylated mRNAs were used in these assays to mimic in vivo decay, which involves cap-stimulated deadenylation by poly (A)-specific ribonuclease (PARN) followed by rapid decay of the mRNA body by the exosome. 
Bcl-2 mRNA Stability is Increased in CLL Cells
fmoles).
Knockdown of Nucleolin Decreases Bcl-2 mRNA Stability and Bcl-2 Protein Levels in Stable
Clones For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From siRNA. The levels of nucleolin mRNA and bcl-2 mRNA in the stable nucleolin siRNA transfected clones were reduced to 24 ± 3 % SEM and 17 ± 5 % SEM, respectively, of the corresponding levels measured in the two MCF-7 clones transfected with the scrambled siRNA.
To compare the relative degrees of bcl-2 mRNA stability in the nucleolin siRNA transfectants versus the scrambled siRNA transfectants we measured the levels of heterogeneous nuclear bcl-2 mRNA and mature bcl-2 mRNA in these transfectants as described in Fig 3. The ratio of the bcl-2 mRNA level to the bcl-2 hnRNA level was about 2.5 fold higher for the scrambled siRNA transfectant compared to the two nucleolin siRNA transfectants (Fig 5) . This suggests that bcl-2 mRNA is relatively less stable in the nucleolin siRNA-transfected MCF-7 clones than in a scrambled siRNA transfectant. Western blot analysis of the transfectants revealed that the levels of full length nucleolin (106 KDa) and its proteolysis products 30 were downregulated in all five clones transfected with the nucleolin siRNA compared to the two clones transfected with the scrambled siRNA (Fig 6) . Equally important, nucleolin knockdown was accompanied by downregulation of bcl-2 protein, but not β -actin, in the five clones transfected with the nucleolin siRNA. These results indicate that downregulation of the bcl-2 mRNA binding protein, nucleolin, leads to bcl-2 mRNA instability and decreased levels of bcl-2 protein.
Discussion
B cell CLL is the most prevalent form of adult leukemia in the Western Hemisphere, partly because the indolent nature of this disease allows for prolonged survival of the patient.
Nevertheless, the clonal B cells accumulate by circumventing the normal B cell apoptotic pathways. 3 The ability of CLL cells to avoid apoptosis complicates the clinical management of the disease with conventional anticancer drugs.
It is known that CLL cells from the majority of patients overexpress bcl-2 protein. [4] [5] [6] However, the molecular basis for the overexpression of bcl-2 protein is less clear, since no cells. This finding is remarkable in that nucleolin is predominately a nuclear protein in most cell types, although a few studies have shown that nucleolin is also present in the cytoplasm and plasma membrane of some tumor cells. [31] [32] [33] The increase in S10 nucleolin levels in the CLL cells was not the result of an increased proliferation rate of the CLL cells compared to the normal B cells, since the CLL cells were clinically indolent and showed no significant thymidine incorporation into DNA (data not shown). The fact that nucleolin was uniformly over-expressed in all our CLL patients, including those in early stages without prior therapy for CLL, suggests only.
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We have previously demonstrated with mRNA decay assays using extracts of HL-60 leukemia cells that exogenous nucleolin binds to an ARE instability element in the 3'-UTR of bcl-2 mRNA and protects this mRNA from degradation. 22 It is thought that stabilizing ARE binding proteins, such as nucleolin, may enhance binding of poly (A) binding protein to translation initiation factors elF4E and elF4G, which circularizes the mRNA. 8 This promotes mRNA stability by inhibiting deadenylation and/or blocking exosome-mediated decay. 8 Our results are consistent with the idea that nucleolin is a bcl-2 mRNA stabilizing protein in CLL cells. Of particular importance is that the overexpressed nucleolin occurs in the cytoplasmic compartment of CLL cells, where it is potentially available to bind to bcl-2 mRNA. Nucleolin has also been shown to bind to the 3'-UTRs of amyloid precursor protein mRNA 34, 35 and human preprorenin mRNA, 36 thereby promoting stabilization of these messages. This protein is likewise involved in the stabilization of IL-2 mRNA that occurs during T cell activation. 21 It was recently reported that about 65% of B cell CLL patients showed either downregulation or deletion of microRNAs miR-15a and miR-16-1. 37 These microRNAs target bcl-2 mRNA and probably interfere with its translation, since they do not appear to affect bcl-2 mRNA levels when transfected into the human megakaryocytic cell line, MEG-O1. However, Cimmino et al 35 did not address the possibility of increased bcl-2 mRNA levels or stability in CLL cells from patients. Thus, it is possible that bcl-2 protein is upregulated in CLL cells as a result of both increased bcl-2 mRNA stability (nucleolin upregulation) and increased bcl-2 mRNA translation (miR-15a, miR-16-1 downregulation). Nevertheless, the results reported herein strongly suggest that increased bcl-2 mRNA stability is an important mechanism involved 
